Replies to post #22144 on Biotech Values

[DewDiligence]

>Dew, with respect to TEVA, you mentioned you might get back in when the stock retraced. Do you have a target for that?<

I would not re-enter in the 40s (barring some colossal change in fundamentals), so it looks like I’ll be on the sidelines for a while.

I consider TEVA a very good company with a bright future, but I do not think of them as a company with some kind of divine intervention. In other words, the usual valuation metrics apply, and TEVA in the 40s is rather expensive in my opinion. Regards, Dew

[io_io]

TEVA:

"I cashed in half of my TEVA chips at around $44"

My humble 2 cents would be to sell the other half too. Praveen pointed out that Teva might be vulnerable to Elan's Tysabri upon it's return, now 2 months away, and I think he's right.